<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02644018</url>
  </required_header>
  <id_info>
    <org_study_id>ING-03-02-2015</org_study_id>
    <nct_id>NCT02644018</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Ingavirin® to Treat Influenza and Other Acute Respiratory Viral Infections in Patients 3-6 y.o.</brief_title>
  <acronym>ACCORD</acronym>
  <official_title>Double Blind Randomized Placebo-controlled Multicenter Study to Evaluate Clinical Efficacy and Safety of Ingavirin®, Capsules 30 mg, in 3-6 Years Old Patients With Influenza and Other Acute Respiratory Viral Infections in the Course of Standard Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valenta Pharm JSC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Atlant Clinical Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Valenta Pharm JSC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Ingavirin ® dosed 30 mg daily is effective
      and safe in the treatment of influenza and other acute respiratory viral infections in the
      course of standard therapy in 3-6 years old patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to decrease in the Influenza and Other ARVI Severity Scale score to 2 points with no more than 1 point at individual subscales and normalization of body temperature</measure>
    <time_frame>5 days</time_frame>
    <description>Temperature normalization means establishment of body temperature below 37 ° C without raising thereafter till 5 days after the treatment start.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to decrease in the Influenza and Other ARVI Severity Scale score to 0 points</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average score at the Influenza and Other ARVI Severity Scale by the 1st, 2nd, 3rd, 4th and 5th days after the start of treatment</measure>
    <time_frame>Within 6 days from the start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The area under the &quot;Influenza and Other ARVI Severity Scale score - time&quot; curve by the 5th day after the start of treatment</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to normalization of body temperature from the start of treatment, measured in hours</measure>
    <time_frame>5 days</time_frame>
    <description>Temperature normalization means establishment of body temperature below 37°C without raising thereafter till 5 days after the treatment start</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The average body temperature by the1st, 2nd, 3rd, 4th and 5th days after the start of treatment</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of patients with normalization of body temperature by the 1st, 2nd, 3rd, 4th and 5th days after the start of treatment</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The area under the &quot;temperature-time&quot; curve by the 5th day after the start of treatment</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of patients with complications of influenza and other ARVI developed over the period from the 1st to the 6th and from the 1st to 14th day after the start of treatment</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of patients with severe complications of influenza and other ARVI that have developed over the period from the 1st to the 6th and from the 1st to 14th day after the start of treatment</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset of complications of influenza and other ARVI from the start of treatment</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>14 days</time_frame>
    <description>Assessment of adverse events (AEs) and serious adverse events (SAEs) by means of -
Portion of patients who developed one or more SAE during the study
Portion of patients who developed one or more AE during the study
Portion of patients who developed one or more severe AE during the study
Portion of patients who developed one or more AE with definite relationship to the investigational product/ placebo during the study
Portion of patients who developed one or more AE with definite or probable relationship to the investigational product/ placebo during the study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">190</enrollment>
  <condition>Common Cold</condition>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Ingavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ingavirin (Imidazolyl ethanamide pentandioic acid), capsules 30 mg daily for 5 days. The contents of one capsule of Ingavirin, capsules 30 mg should be dissolved in 50-70 ml of water at room temperature or apple juice at room temperature with mandatory stirring for 20 seconds and administered orally 1 time a day regardless of the meal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, capsules daily for 5 days. The contents of one capsule of placebo should be dissolved in 50-70 ml of water at room temperature or apple juice at room temperature with mandatory stirring for 20 seconds and administered orally 1 time a day regardless of the meal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imidazolyl ethanamide pentandioic acid</intervention_name>
    <arm_group_label>Ingavirin</arm_group_label>
    <other_name>Ingavirin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The informed consent form signed by the patient's parent/adoptive parent to
             participate in the clinical study.

          -  Male and female patients aged 3-6.

          -  Patients with moderate course of influenza or other acute respiratory viral
             infections.

          -  Patients with clinically diagnosed influenza or other ARVI based on the body
             temperature &gt; 37,5 ° C, not less than 1 of the following other symptoms of
             intoxication and not less than 1 of the following of catarrhal symptoms:

               -  Intoxication symptoms: headache, malaise, myalgia, pain in the eyeballs;

               -  Catarrhal symptoms: sore throat, rhinorrhea, cough, nasal congestion.

          -  Established diagnosis J06.9, J10, J11, in accordance with ICD-10.

          -  Uncomplicated course of influenza and other ARVI.

          -  Interval between onset of symptoms and enrollment to the study of not more than 36
             hours.

        Exclusion Criteria:

          -  Complicated course of influenza and other acute respiratory viral infections.

          -  Treatment with antiviral drugs (antivirals, interferons and interferon inducers),
             drugs with immunomodulatory effects or antibiotics with systemic and local action
             within 14 days prior to the screening visit.

          -  Severe influenza or other ARVI with symptoms of cardiovascular disease, and other
             symptoms of infectious-toxic shock, and meningoencephalitic syndromes.

          -  Signs of primary viral pneumonia development (presence of two or more of the following
             symptoms): shortness of breath, chest pain when coughing, systemic cyanosis, dullness
             of percussion sound at symmetrical assessment of the upper and lower parts of the
             lungs.

          -  Infectious diseases within the last week prior to enrollment.

          -  &quot;RRI children&quot; (incidence of ARVI within the last 12 months is 6 times or more).

          -  Asthma history.

          -  History of increased seizure activity.

          -  Severe decompensated or unstable medical or psychiatric conditions (any diseases or
             conditions that threaten the life of the patient or worsen the patient's prognosis and
             also make it impossible to conduct a clinical study in the patient).

          -  Cancer, HIV infection, tuberculosis, including those in history.

          -  Hypersensitivity to imidazolyl ethanamide pentandioic acid and/or excipients of
             Ingavirin product.

          -  Diabetes, lactose intolerance, lactase deficiency, glucose-galactose malabsorption,
             deficiency of sucrase/isomaltase, fructose intolerance, hereditary glucose
             malabsorption, deficiency of glucose-6-phosphate dehydrogenase.

          -  Participation of the patient in any other clinical trial within the last 90 days prior
             to enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ekaterina Zakharova, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Valenta Pharm JSC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yuriy V. Lobzin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scientific Research Institute of Children's Infections, Federal Biomedical Agency, Saint-Petersburg, Russian Federation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GBOU VPO &quot;Kazan State Medical University&quot; of Ministry of Health of Russian Federation</name>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GBOU VPO &quot;Krasnoyarsk State Medical University n.a.n V.F. Voyno-Yasenetskogo&quot; of Ministry of Health of Russian Federation</name>
      <address>
        <city>Krasnoyarsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FGBU &quot;Scientific center of children health&quot; of the Ministry of Health of Russian Federation</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>I.M. Sechenov First Moscow State Medical University</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow Budgetary Public Health Facility &quot;Infectious clinical hospital #1&quot; of Moscow City Health Department</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GBOU VPO &quot;Novosibirsk State Medical University of Ministry of Health of Russian Federation&quot;</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's city outpatients clinic № 5</name>
      <address>
        <city>Perm</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's city outpatients clinic № 4</name>
      <address>
        <city>Rostov-na-Donu</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GBOU VPO &quot;Rostov State Medical University&quot; of Ministry of Health of Russian Federation</name>
      <address>
        <city>Rostov-na-Donu</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FGBU &quot;Scientific Research Institute of Children's Infections, Federal Biomedical Agency&quot;</name>
      <address>
        <city>Saint-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FGBOU VPO &quot;Mordov State University n.a. N.P. Ogarev&quot;</name>
      <address>
        <city>Saransk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GBOU VPO &quot;Siberia State Medcial University&quot; of Ministry of Health of Russian Federation</name>
      <address>
        <city>Tomsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GBOU VPO &quot;Yaroslavl State Medical University&quot; of Ministry of Health of Russian Federation</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2015</study_first_submitted>
  <study_first_submitted_qc>December 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2015</study_first_posted>
  <last_update_submitted>June 7, 2016</last_update_submitted>
  <last_update_submitted_qc>June 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ingavirin</keyword>
  <keyword>Common Cold</keyword>
  <keyword>Influenza</keyword>
  <keyword>Acute Respiratory Viral Infections</keyword>
  <keyword>pediatric clinical trial</keyword>
  <keyword>Imidazolyl ethanamide pentandioic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Common Cold</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

